The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
Official Title: A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
Study ID: NCT01134640
Brief Summary: A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final evaluable cases.
Detailed Description:
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Chang Gung Medical Foundation, Chiayi, , Taiwan
Chiayi Christian Hospital, Chiayi, , Taiwan
Buddhist Tzu Chi General Hospital, Hualien, , Taiwan
Chang Gung Medical Foundation, Kaohsiung, , Taiwan
Chang Gung Medical Foundation, Keelung, , Taiwan
Chang Gung Medical Foundation, LinKou, , Taiwan
Chung Shan Medical University Hospital, Taichung, , Taiwan
Taichung Veterans General Hospital, Taichung, , Taiwan
Chi Mei Medical Center, Liou Ying, Tainan, , Taiwan
Chi Mei Medical Center, Yongkang, Tainan, , Taiwan
National Cheng Kung University Hospital, Tainan, , Taiwan
Tainan Municipal Hospital, Tainan, , Taiwan
Buddhist Tzu Chi General Hospital, Taipei, , Taiwan
Mackay Memorial Hospital, Taipei, , Taiwan
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, , Taiwan
Name: Jade Lien
Affiliation: Merck Ltd., Taiwan
Role: STUDY_DIRECTOR